Translation towards personalized medicine in Multiple Sclerosis

摘要: In recent years the realization that concept 'one drug fits all' - does not work, created need to shift gears from 'treating disease' patient', and implementation of 'Personalized Medicine' where treatment is tailored individual. chronic progressive diseases, such as Multiple Sclerosis (MS), for therapeutics especially imperative, consequences an ineffective medication might be irreversible dysfunction. accumulating evidence indicates MS a single disease patients with different subtypes respond differently medication. Environment genetics are among factors determine subtype activity, patient's response Additional include demographic characteristics gender age, well chrono-biological indicators. During last few years, advances availability new technologies have brought genome-wide gene expression profiling studies many medical fields, including MS. Genomic also stimulated pharmacogenetics studies, aim identify genetic affect treatment. However, information still immature allow its translation clinical practice in Notably, one major limitations obtaining reproducible data across has been lack consensus appropriate method determining response. light rapid technology progress applying individualized strategies other seems feasible within coming years.